v3.25.2
Collaborative Arrangements and Licensing Agreements - Additional Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended 12 Months Ended
Jul. 12, 2024
Dec. 20, 2023
Sep. 28, 2023
Aug. 05, 2021
May 01, 2021
Jan. 05, 2021
Apr. 29, 2020
Jan. 31, 2019
Jun. 30, 2025
Sep. 30, 2024
Jun. 30, 2025
Dec. 31, 2024
Dec. 31, 2023
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Initial transaction price of upfront payment     $ 7,000                    
Payment Deposit Fee Received                   $ 700      
Revenues                 $ 0   $ 800 $ 3,500 $ 7,962
License [Member]                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Amount of limited payment for discharge agreement         $ 20,000                
IMG 013 Agreement                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Upfront consideration payment $ 3,500                        
Amount received from the upfront payment 3,500                        
Collaboration revenue                       3,500  
IMG 013 Agreement Based On Development And Milestone | Maximum                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Upfront consideration payment 66,000               66,000        
IMG 013 Agreement Based On Development And Milestone | Minimum                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Upfront consideration payment 63,000               63,000        
IMG 013 Agreement Based On Sales Milestone                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Upfront consideration payment 285,000                        
Celexor Agreement                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Upfront consideration payment     $ 7,000                    
Issuance of common stock for underwritten registered offering, net of offering costs, Shares     1,223,300                    
Issuance of common stock for underwritten registered offering, net of offering costs     $ 900                    
Collaboration revenue                         7,900
Celexor Agreement | Celexor Series Seed-2 Preferred Shares                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Issuance of common stock for underwritten registered offering, net of offering costs, Shares     1,223,300                    
Issuance of common stock for underwritten registered offering, net of offering costs     $ 900                    
Preferred shares     900                    
Celexor Agreement Based On Development And Milestone                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Upfront consideration payment     112,000                    
Celexor Agreement Based On Sales Milestone                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Upfront consideration payment     $ 175,000                    
Img 008 Agreement                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Upfront consideration payment 6,500               700        
Payment For One Time Settlement Amount                 100        
Deposit Of Upfront Payment                       700  
Kissei Agreement [Member]                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Upfront payment       $ 1,000                  
Payment for agreement       2,000                  
Amount of limited payment for discharge agreement   $ 2,000                      
Kissei Agreement Based On Development And Milestone [Member]                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Upfront consideration payment       40,000                  
Kissei Agreement Based On Sales Milestone [Member]                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Upfront consideration payment       $ 12,000                  
Hutchmed Agreement [Member]                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Issuance of common stock for underwritten registered offering, net of offering costs                       14,000  
Hutchmed Agreement [Member] | License [Member]                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
License fee           $ 20,000              
Affibody Agreement [Member]                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Upfront payment             $ 10,000            
Affibody Agreement Based On Development And Milestone [Member]                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Upfront consideration payment         92,500   37,500            
Affibody Agreement Based On Sales Milestone [Member]                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Upfront consideration payment         $ 135,000   178,000            
global Development Regulatory and Salesbased Milestones [Member]                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Additional Amount Eligible to Receive Under Agreement             $ 36,000            
Hutchmed Agreement Based On Development And Milestone [Member]                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Upfront consideration payment           $ 92,500              
Issuance of common stock for underwritten registered offering, net of offering costs, Shares         140,636,592 140,636,592              
Issuance of common stock for underwritten registered offering, net of offering costs                       14,000  
Hutchmed Agreement Based On Sales Milestone [Member]                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Upfront consideration payment           $ 135,000              
IMG 008Agreement Based On Development And Milestone [Member]                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Upfront consideration payment 86,500                        
IMG 008Agreement Based On Sales Milestone [Member]                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Upfront consideration payment $ 285,000                        
IKENA ONCOLOGY INC                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Issuance of common stock for underwritten registered offering, net of offering costs                         37,421
Preferred shares                 $ 0   $ 0 0 0
Collaboration revenue                       $ 0 9,160
IKENA ONCOLOGY INC | Bristol Myers Squibb Collaboration Agreement and Stock Purchase Agreement | BMS                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Upfront consideration payment               $ 95,000          
IKENA ONCOLOGY INC | Bristol Myers Squibb Collaboration Agreement and Stock Purchase Agreement | BMS | Maximum                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Milestone payments eligible to receive               450,000          
IKENA ONCOLOGY INC | Bristol Myers Squibb Collaboration Agreement and Stock Purchase Agreement | BMS | IK-175                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Amount eligible to receive in case of exercise of options               50,000          
IKENA ONCOLOGY INC | Bristol Myers Squibb Collaboration Agreement and Stock Purchase Agreement | BMS | IK-412                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Amount eligible to receive in case of exercise of options               40,000          
IKENA ONCOLOGY INC | Bristol Myers Squibb Collaboration Agreement                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Transaction price allocated to revenue arrangement               78,700          
Revenue recognized which were previously included in deferred revenue                         $ 9,200
IKENA ONCOLOGY INC | Bristol Myers Squibb Collaboration Agreement | BMS                          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                          
Upfront consideration payment               $ 78,700